You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
United said it will distribute the test to international governments and healthcare organizations.
Under the agreement, Bioneer will supply instruments, nucleic acid extraction reagents, and COVID-19 test kits, which will be placed at medical institutions in Qatar.
The three hospital laboratories' tests are all real-time PCR assays for detecting the virus from nasopharyngeal swabs and bronchoalveolar lavage.
The test is a real-time RT-PCR kit designed to detect SARS-CoV-2 in nasopharyngeal and oropharyngeal swabs, as well as bronchoalveolar lavage.
The test, developed by the firms in six weeks, is part of a viral respiratory panel and runs on Bosch's point-of-care Vivalytic system.
Under the guidance, only the laboratory that developed the test can perform it if the lab is CLIA-certified to perform high-complexity tests.
Color is opening a lab dedicated to SARS-CoV-2 testing and adapting its software infrastructure to enable physicians to order tests and return results.
Sysmex anticipates delivering the kit to Japanese medical institutions this month for diagnosis of the SARS-CoV-2 infection.
Biocartis will lead commercialization in Europe as the exclusive distributor of the SeptiCyte Rapid test, while Immunexpress will lead commercialization of the test in the US.
The company's in vitro diagnostic qRT-PCR test detects viral RNA and targets three genes of the SARS-CoV-2 virus: the N, Orf1ab, and E genes.